MarketCapExport financials
Anavex Life Sciences Corp. (AVXL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Anavex Life Sciences Corp. Balance Sheet 2025-2004 | AVXL
Brief overview of Anavex Life Sciences Corp.'s balance sheet strength
The review uses the five latest available annual reports between 2021 and 2025.
Across five reporting periods, assets decreased -35.8%, from $161.6 million to $103.8 million, producing a negative trend.
Liabilities grew faster than assets: -17.2% versus -35.8%. A substantial part of expansion was externally funded.
The equity-to-assets ratio is 91.4%, compared with 93.3% five periods ago. The balance sheet has a substantial internal cushion.
The cash reserve occupies 98.8% of the balance sheet, previously 94.1%. It is one marker of short-term resilience.
The accumulated result is -$382.4 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Anavex Life Sciences Corp.'s financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Anavex Life Sciences Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | - | - | -22.2 M | -22.9 M | -27.4 M | -9.19 M | -15.2 M | -1.35 M | -134 K | 288 K | 733 K | - | - | - | - | - | - | - |
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | 332 | 5.72 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | 332 | 5.72 M | 904 K | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
- | - | - | - | - | - | 5.04 M | 3.88 M | 3.58 M | 3.19 M | 2.66 M | 1.44 M | 1.95 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.95 M | 15.3 M | 12.5 M | 10.2 M | 10.8 M | 7.31 M | 5.04 M | 3.88 M | 3.58 M | 3.19 M | 2.66 M | 7.16 M | 2.86 M | 2.89 M | 1.35 M | 3.29 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | 70.5 K | 71.6 K | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-382 M | -336 M | -293 M | -246 M | -198 M | -160 M | -133 M | -109 M | -91.5 M | -78 M | -63.3 M | -52.6 M | -41.2 M | -37.5 M | -29.2 M | - | - | - | - | - | - | - |
Total Assets |
104 M | 136 M | 154 M | 153 M | 162 M | 34.5 M | 25.3 M | 24.4 M | 27.8 M | 9.5 M | 15.5 M | 7.35 M | 393 K | 13.2 K | 203 K | 330 K | - | - | - | - | - | - |
Cash and Cash Equivalents |
103 M | 132 M | 151 M | 149 M | 152 M | 29.2 M | 22.2 M | 22.9 M | 27.4 M | 9.19 M | 15.3 M | 7.26 M | 345 K | 11.4 K | 135 K | 265 K | 351 K | - | - | - | - | - |
Book Value |
94.9 M | 120 M | 142 M | 142 M | 151 M | 27.2 M | 20.3 M | 20.5 M | 24.3 M | 6.31 M | 12.8 M | 193 K | -2.46 M | -2.88 M | -1.14 M | -2.96 M | - | - | - | - | - | - |
Total Shareholders Equity |
94.9 M | 120 M | 142 M | 142 M | 151 M | 27.2 M | 20.3 M | 22.3 M | 24.3 M | 6.31 M | 12.8 M | 193 K | -2.46 M | -2.88 M | -1.14 M | -2.96 M | -3.86 M | -2.29 M | -463 K | -15.5 K | -26 K | 25.6 K |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Anavex Life Sciences Corp.
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 345 | 337 | 265 | 332 | 332 | 332 | - | 5.72 M | 1.09 K | 1.01 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.95 M | 8.95 M | 8.95 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 13.1 M | 15.3 M | 11.8 M | 9.56 M | 12.5 M | 12.5 M | 11.1 M | 14 M | 13.2 M | 10.2 M | - | - | - | 10.8 M | 9.27 M | - | - | 7.31 M | - | - | - | 5.04 M | - | - | - | - | - | - | - | 3.58 M | - | - | - | 3.19 M | 2.17 M | 2.43 M | 2.53 M | 2.66 M | 2.66 M | 2.66 M | 6.58 M | 7.16 M | 7.16 M | 7.16 M | 1.82 M | 2.86 M | 2.86 M | 2.86 M | 3.41 M | 2.89 M | 2.89 M | 2.89 M | 2.57 M | 1.35 M | 1.35 M | 1.35 M |
Retained Earnings |
-382 M | -382 M | -382 M | -336 M | -336 M | -336 M | -336 M | -348 M | -336 M | -324 M | -312 M | -302 M | -293 M | -283 M | -272 M | -259 M | -246 M | -231 M | -219 M | -208 M | -198 M | -186 M | -198 M | -168 M | -160 M | -160 M | -160 M | -140 M | -133 M | -133 M | -133 M | -116 M | -107 M | -109 M | -109 M | -95.5 M | -91.5 M | -91.5 M | -91.5 M | -81.2 M | -78 M | -78 M | -78 M | -67.2 M | -63.3 M | -63.3 M | -63.3 M | - | -51.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
104 M | 104 M | 104 M | 136 M | 136 M | 136 M | 136 M | 124 M | 136 M | 142 M | 145 M | 148 M | 154 M | 158 M | 159 M | 148 M | 153 M | 160 M | 160 M | 157 M | 162 M | 166 M | 162 M | 54.3 M | 34.5 M | 34.5 M | 34.5 M | 31.4 M | 25.3 M | 25.3 M | 25.3 M | 22.1 M | 26.2 M | 24.4 M | 24.4 M | 28.3 M | 27.8 M | 27.8 M | 27.8 M | 21.4 M | 9.5 M | 9.5 M | 9.5 M | 14 M | 15.5 M | 15.5 M | 15.5 M | 7.05 M | 7.35 M | 7.35 M | 7.35 M | 151 K | 393 K | 393 K | 393 K | 79.9 K | 13.2 K | 13.2 K | 13.2 K | 84.6 K | 203 K | 203 K | 203 K |
Cash and Cash Equivalents |
132 M | 132 M | 132 M | 149 M | 151 M | 151 M | 151 M | 121 M | 132 M | 139 M | 139 M | 144 M | 151 M | 155 M | 153 M | 144 M | 149 M | 153 M | 153 M | 151 M | 152 M | 158 M | 152 M | 47.4 M | 29.2 M | 29.2 M | 47.4 M | 27.5 M | 22.2 M | 22.2 M | 22.2 M | 20.7 M | 22.9 M | 25.8 M | 25.7 M | 28 M | 27.4 M | 24.8 M | 23.4 M | 21.2 M | 9.19 M | 9.19 M | 21.2 M | 13.9 M | 15.3 M | 15.3 M | 13.9 M | 6.98 M | 7.26 M | 7.26 M | 6.98 M | 95.9 K | 345 K | 345 K | 95.9 K | 79.8 K | 11.4 K | 11.4 K | 79.8 K | 9.08 K | 135 K | 135 K | 9.08 K |
Book Value |
94.9 M | 94.9 M | 94.9 M | 120 M | 120 M | 120 M | 120 M | 111 M | 120 M | 130 M | 135 M | 136 M | 142 M | 147 M | 145 M | 135 M | 142 M | 160 M | 160 M | 157 M | 151 M | 157 M | 162 M | 54.3 M | 27.2 M | 34.5 M | 34.5 M | 31.4 M | 20.3 M | 25.3 M | 25.3 M | 22.1 M | 26.2 M | 24.4 M | 24.4 M | 28.3 M | 24.3 M | 27.8 M | 27.8 M | 21.4 M | 6.31 M | 7.33 M | 7.07 M | 11.5 M | 12.8 M | 12.8 M | 12.8 M | 473 K | 193 K | 193 K | 193 K | -1.67 M | -2.46 M | -2.46 M | -2.46 M | -3.33 M | -2.88 M | -2.88 M | -2.88 M | -2.48 M | -1.14 M | -1.14 M | -1.14 M |
Total Shareholders Equity |
120 M | 120 M | 120 M | 142 M | 142 M | 142 M | 142 M | 111 M | 120 M | 130 M | 135 M | 136 M | 142 M | 147 M | 145 M | 135 M | 142 M | 151 M | 152 M | 146 M | 151 M | 157 M | 75.8 M | 46.3 M | 27.2 M | 46.3 M | 46.3 M | 26 M | 20.3 M | 26 M | 26 M | 19.5 M | 22.3 M | 17.2 M | 17.2 M | 25.5 M | 25.9 M | 24.3 M | 25.5 M | 19.2 M | 6.31 M | 6.31 M | 6.31 M | 11.5 M | 12.8 M | 12.8 M | 12.8 M | 473 K | 193 K | 193 K | 193 K | -1.67 M | -2.46 M | -2.46 M | -2.46 M | -3.33 M | -2.88 M | -2.88 M | -2.88 M | -2.48 M | -1.14 M | -1.14 M | -1.14 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Anavex Life Sciences Corp., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Insmed Incorporated
INSM
|
$ 96.27 | 1.45 % | $ 19.2 B |  USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 10.78 | 4.62 % | $ 697 M | USA |
 |
Biogen
BIIB
|
$ 232.65 | 0.1 % | $ 34.1 B | USA |
 |
BioVie
BIVI
|
$ 1.2 | 6.19 % | $ 1.77 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 42.94 | 3.33 % | $ 6.87 B | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.43 | 0.54 % | $ 128 M |  France |
 |
NextCure
NXTC
|
$ 6.24 | 4.56 % | $ 17.7 M | USA |
 |
BeyondSpring
BYSI
|
$ 0.56 | 3.09 % | $ 23 M | USA |
 |
Capricor Therapeutics
CAPR
|
$ 6.71 | 10.32 % | $ 312 M | USA |
 |
Oncolytics Biotech
ONCY
|
$ 0.5 | 1.75 % | $ 47.9 M |  Canada |
 |
Outlook Therapeutics
OTLK
|
$ 0.49 | 0.04 % | $ 17.1 M | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 128.75 | 0.2 % | $ 8.19 B | USA |
 |
Passage Bio
PASG
|
$ 3.5 | 4.44 % | $ 11.2 M | USA |
 |
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 80.14 | 3.04 % | $ 4.02 B | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.65 | 1.67 % | $ 162 M | USA |
|
Immatics N.V.
IMTX
|
$ 6.73 | 2.0 % | $ 823 M |  Germany |
 |
Immunic
IMUX
|
$ 6.97 | 0.56 % | $ 1.09 B | USA |
 |
Immunovant
IMVT
|
$ 26.73 | 0.57 % | $ 4.88 B | USA |
 |
MediciNova
MNOV
|
$ 1.42 | 0.69 % | $ 69.7 M | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 13.62 | 3.59 % | $ 4.87 M | USA |
|
Rezolute
RZLT
|
$ 3.58 | 0.12 % | $ 372 M | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Canada |
 |
Krystal Biotech
KRYS
|
$ 316.58 | 0.82 % | $ 9.16 B | USA |
 |
Nektar Therapeutics
NKTR
|
$ 35.78 | 2.25 % | $ 604 M | USA |
 |
NanoViricides
NNVC
|
$ 1.38 | 0.73 % | $ 27.9 M | USA |
 |
Grifols, S.A.
GRFS
|
$ 7.64 | 1.33 % | $ 5.19 B |  Spain |
 |
Nurix Therapeutics
NRIX
|
$ 24.42 | 0.12 % | $ 2.12 B | USA |
 |
Ocugen
OCGN
|
$ 0.78 | 0.06 % | $ 244 M | USA |
 |
Oragenics
OGEN
|
$ 0.43 | 1.69 % | $ 928 K | USA |
 |
Omeros Corporation
OMER
|
$ 16.2 | 1.95 % | $ 1.03 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
$ 12.35 | 10.18 % | $ 1.08 B | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.86 | 3.06 % | $ 48 M | USA |
 |
Alkermes plc
ALKS
|
$ 41.22 | 2.79 % | $ 6.79 B |  Irlanda |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 210.23 | 2.28 % | $ 12.8 B | Irlanda |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.87 | 0.05 % | $ 5.21 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 104.78 | 1.23 % | $ 8.85 B | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 241.76 | 3.86 % | $ 5.44 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.31 | 0.34 % | $ 138 M |  Niderland |
 |
PTC Therapeutics
PTCT
|
$ 59.24 | 2.21 % | $ 4.71 B | USA |
 |
Arcus Biosciences
RCUS
|
$ 22.12 | 1.26 % | $ 2.38 B | USA |
|
Larimar Therapeutics
LRMR
|
$ 1.99 | 1.51 % | $ 165 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 790.74 | 0.01 % | $ 82.7 B | USA |
 |
Rafael Holdings
RFL
|
$ 1.39 | 2.8 % | $ 40.9 M | USA |
 |
REGENXBIO
RGNX
|
$ 6.93 | 4.07 % | $ 357 M | USA |
 |
Royalty Pharma plc
RPRX
|
$ 60.96 | 2.25 % | $ 26.2 B | USA |
 |
Seer
SEER
|
$ 2.03 | 0.44 % | $ 112 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.13 | 0.62 % | $ 52.4 M | USA |
 |
SIGA Technologies
SIGA
|
$ 3.17 | 0.16 % | $ 227 M | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 21.3 | 4.46 % | $ 1.02 T | France |